PURPOSE: It was our aim to determine baseline levels of testicular cancer and genetics knowledge among members of families with Familial Testicular Cancer (FTC). METHODS: This is a sub-study of an ongoing National Cancer Institute (NCI) multidisciplinary, etiologically-focused, cross-sectional study of FTC. We evaluated 258 male and female participants including testicular cancer (TC) survivors, blood relatives and spouses to assess factors associated with a Genetic Knowledge Scale (GKS) and Testicular Cancer Knowledge Scale (TCKS). RESULTS: Knowledge levels were generally low, with genetic knowledge lower than TC knowledge (p < 0.01). Men with a personal TC history scored highest on TC knowledge, while gender, age and education differentially influenced knowledge levels, particularly among unaffected relatives. CONCLUSIONS: Prior to identifying FTC susceptibility genes, we recommend tailoring FTC genetic education to the different informational needs of TC survivors, their spouses and relatives, in preparation for the day when clinical susceptibility testing may be available.
PURPOSE: It was our aim to determine baseline levels of testicular cancer and genetics knowledge among members of families with Familial Testicular Cancer (FTC). METHODS: This is a sub-study of an ongoing National Cancer Institute (NCI) multidisciplinary, etiologically-focused, cross-sectional study of FTC. We evaluated 258 male and female participants including testicular cancer (TC) survivors, blood relatives and spouses to assess factors associated with a Genetic Knowledge Scale (GKS) and Testicular Cancer Knowledge Scale (TCKS). RESULTS: Knowledge levels were generally low, with genetic knowledge lower than TC knowledge (p < 0.01). Men with a personal TC history scored highest on TC knowledge, while gender, age and education differentially influenced knowledge levels, particularly among unaffected relatives. CONCLUSIONS: Prior to identifying FTC susceptibility genes, we recommend tailoring FTC genetic education to the different informational needs of TC survivors, their spouses and relatives, in preparation for the day when clinical susceptibility testing may be available.
Authors: Joan L Bottorff; Pamela A Ratner; Lynda G Balneaves; Chris G Richardson; Mary McCullum; Tom Hack; Karen Chalmers; Jane Buxton Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-01 Impact factor: 4.254
Authors: C Lerman; B Biesecker; J L Benkendorf; J Kerner; A Gomez-Caminero; C Hughes; M M Reed Journal: J Natl Cancer Inst Date: 1997-01-15 Impact factor: 13.506
Authors: Mark H Greene; Christian P Kratz; Phuong L Mai; Christine Mueller; June A Peters; Gennady Bratslavsky; Alex Ling; Peter M Choyke; Ahalya Premkumar; Janet Bracci; Rissah J Watkins; Mary Lou McMaster; Larissa A Korde Journal: Endocr Relat Cancer Date: 2010-03-08 Impact factor: 5.678
Authors: Jada G Hamilton; Sadie P Hutson; Amy E Frohnmayer; Paul K J Han; June A Peters; Ann G Carr; Blanche P Alter Journal: J Genet Couns Date: 2014-12-27 Impact factor: 2.537
Authors: June A Peters; Regina Kenen; Lindsey M Hoskins; Gladys M Glenn; Christian Kratz; Mark H Greene Journal: Hered Cancer Clin Pract Date: 2012-03-01 Impact factor: 2.857
Authors: Susanne F Meisel; Maddie Freeman; Jo Waller; Lindsay Fraser; Sue Gessler; Ian Jacobs; Jatinderpal Kalsi; Ranjit Manchanda; Belinda Rahman; Lucy Side; Jane Wardle; Anne Lanceley; Saskia C Sanderson Journal: BMC Public Health Date: 2017-11-16 Impact factor: 3.295